Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05500508 · ClinicalTrials.gov registry record · Phase 1

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

A Phase 1 study, sponsored by Aminex Therapeutics.

Terminated
Registry status
Phase 1
Development phase
15
Enrollment target

NCT05500508: Clinical Trial Phase 1 study, sponsored by Aminex Therapeutics.

NCT05500508 is a Phase 1 study that was terminated before completion, run by Aminex Therapeutics. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05500508, a Phase 1 study, was terminated before completion, sponsored by Aminex Therapeutics.

TERMINATED
Registry status
Phase 1
Development phase
15 participants
Enrollment target

Study Summary

A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.

Primary Outcome

Indicate Number of patients with DLTs in AMXT1501 in combination with IV DFMO in patients with advanced cancer to determine the RP2D within the duration of the dose escalation period of the study as defined by the DLT definition of the protocol from baseline to end of Cycle 1

Interventions

  • DRUG DFMO
  • DRUG AMXT1501

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2022-11-29
Est. Completion 2024-12-12
Phase Phase 1
Aminex Therapeutics

3 total trials

Why NCT05500508 stopped before completion

NCT05500508 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).

The record links to 0 conditions, and to 2 interventions - of which DFMO is the first listed.

NCT05500508 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05500508 about?

NCT05500508 is a clinical study titled "Oral AMXT 1501 Dicaprate in Combination With IV DFMO". A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.

What is the current status of trial NCT05500508?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2022-11-29. Estimated completion is 2024-12-12.

What interventions are being tested in trial NCT05500508?

The interventions under investigation include: DFMO (DRUG), AMXT1501 (DRUG).

Who is sponsoring clinical trial NCT05500508?

This trial is sponsored by Aminex Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05500508's enrollment target sits among peer trials

15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05500508, the US trial registry maintained by the National Library of Medicine. NCT05500508 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.